Current Report · Items 7.01, 9.01 · 8-K

GlucoTrack, Inc.

Regulation FD Disclosure

Filed May 13, 2025Accepted May 13, 2025, 8:45 AM EDTCIK 1506983Accession 0001641172-25-009849

Company context

Inc. Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.

Current securities

GCTKOTC · EQUITY · Current

Historical securities (2)

GCTKNASDAQ · EQUITY · Historical · closed Oct 19, 2026 IGAPOTC · EQUITY · Historical · closed Aug 13, 2021

Recent company filings

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On May 13, 2025, Glucotrack, Inc., a Delaware corporation (the “Company”) issued a press release (the “Press Release”). The Press Release is furnished herewith as Exhibit 99.1. The information presented in Item 7.01 of this Current Report on Form 8-K and the accompanying Press Release shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference into any filing with the Securities and Exchange Commission, except as expressly set forth by specific reference in such a filing.

Filed exhibits (1)

EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 GLUCOTRACK ANNOUNCES ETHICAL APPROVAL FOR LONG-TERM CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR Long-term clinical evaluation represents key advancement following successful first-in-human study Rutherford, NJ, May 13, 2025 (GLOBE NEWSWIRE) - Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced it has received ethical approval from the St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) for its long-term clinical study of the Company’s continuous blood glucose monitor (“CBGM”) in participants with type 1 and type 2 diabetes. The prospective, single arm, multi-center study will enroll up to 30 participants with type 1 and type 2 diabetes mellitus requiring glucose monitoring and intensive insulin therapy. The study will evaluate the device’s performance and safety over an initial period of 1 year. The Company may complete additional submissions to extend the study to 3 years, upon completion of the initial study period. With this approval and per the …

Open exhibit ↗

Get the free weekly BCS email.